gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · INVAHealthcarePharmaceuticals

Innoviva, Inc. Common Stock (INVA)

$21.26+1.58%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$20.93▲ 15.57% in range
Nov 3, 2025Low $18.11 · High $24.24Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Innoviva closed at $21.26 on Nov 4, up 1.58%, 12.3% below its 52-week closing high. Volume of 919.7K shares was 1.44× its 20-day average (above normal).

Split-adjusted performance: +2.1% over one month, -5.6% over six months, +17.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $119.59M, up 19.3% from a year earlier, with a net margin of -69.8%.

Short interest was 7.3M shares at the Oct 15 settlement, up 6.1% from the prior report (10.5% of float, 10.4 days to cover).

Market cap$1.54B72.2M shares
Revenue · quarter$119.6M+19.3% YoY
Diluted EPS$-1.14−248.1% YoY
P/E · TTM4.3×P/S 3.5×
Net margin-69.8%Gross 81.3%
Dividend yieldNone$0.25 last paid
52-week range18.11 – 24.24−12.3% from high
Volume919.7K1.44× 20-day avg
Volatility · 60d21.1%Annualised
Short % of float10.5%10.4 days to cover
Net cash$319.0MCash $579.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +0.7%1M +2.1%3M +0.7%6M −5.6%YTD +6.4%1Y +17.4%3Y +71.2%5Y +32.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum67
Revenue growth66
Net margin44
Value (low P/E)88
Size76

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short7.3M+6.1% vs prior
Days to cover10.4Settled Oct 15
% of float10.5%
Short vol. 10d46.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
INVAInnoviva$21.26+1.58%−5.6%+19.3%−69.8%4.3$1.54B
OCULOcular Therapeutix$7.14+4.69%−26.5%+0.1%−584.5%—$1.57BCompare
MLYSMineralys Therapeutics$17.00+6.32%−43.6%———$1.50BCompare
TYRATyra Biosciences$21.53+0.73%−36.3%———$1.48BCompare
QUREuniQure$23.03−3.52%+0.9%+11.0%−1387.8%—$1.60BCompare
PAHCPhibro Animal Health$39.43+4.73%−32.6%+4.8%5.5%16.1$1.60BCompare
RAPPRapport Therapeutics$25.93+1.93%−30.0%———$1.46BCompare
KARDKardigan$15.56+8.66%————$1.45BCompare
PCRXPacira BioSciences$36.40+0.03%+53.7%+6.2%2.4%99.2$1.45BCompare

News about Innoviva

All news →
INVA vs. MRK: Which Stock Is the Better Value Option?Zacks Investment Research · Oct 8, 2026▲ PositiveShould Value Investors Buy Innoviva (INVA) Stock?Zacks Investment Research · Oct 8, 2026▲ Positive

Quick answers

What does Innoviva do?
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets.
What is INVA's market cap?
$1.54B, based on the Nov 4 close of $21.26.
What is INVA's P/E ratio?
4.3× trailing-twelve-month earnings of $357.24M.
Does Innoviva pay a dividend?
No regular cash dividend has been paid in the last year.
How much of INVA is sold short?
7.3M shares, 10.5% of float, as of Oct 15, 2026.
What sector is INVA in?
Healthcare, in the Pharmaceuticals industry.

About Innoviva

Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.

HQ: Burlingame, CA159 employeesListed Oct 5, 2004inva.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology